Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

05-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Ribociclib efficacy for visceral metastases

Denise Yardley reports on the outcomes of participants with visceral metastases in the MONALEESA-3 and MONALEESA-7 trials of ribociclib for hormone receptor-positive, HER2-negative breast cancer (8:54).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

02-04-2019 | Advanced breast cancer | Editorial | Article

The use of CDK4/6-inhibitors in advanced, hormone-receptor positive breast cancer: why, when and who?

31-05-2018 | Hormone-receptor positive breast cancer | News

Ribociclib addition boosts endocrine therapy in premenopausal women with advanced breast cancer
Image Credits